Atossa Therapeutics Inc(ATOS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.34 | Insider Own | 1.52% | Shs Outstand | 10.0M | Perf Week | -10.55% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 25.71% | Insider Trans | - | Shs Float | 9.8M | Perf Month | -13.47% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.86 | Inst Own | 13.47% | Short Float | 6.95% | Perf Quarter | -12.4% |
| Income | -0.04B | P/S | - | EPS this Y | 7.26% | Inst Trans | 1.11% | Short Ratio | 9.63 | Perf Half Y | -63.45% |
| Sales | 0.00B | P/B | 0.79 | EPS next 5Y | - | ROA | -77.91% | Short Interest | 0.68M | Perf YTD | -76.05% |
| Book/sh | 2.69 | P/C | 0.81 | EPS past 3/5Y | -8.13% 32.87% | ROE | -89.23% | 52W High | -85.72% ($14.85) | Perf Year | -83.34% |
| Cash/sh | 2.63 | P/FCF | - | Sales past 3/5Y | - | ROIC | -140.55% | 52W Low | 24.71% ($1.70) | Perf 3Y | -79.81% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -28.83% | Gross Margin | - | Volatility(W/M) | 8.96% 10.79% | Perf 5Y | -94.97% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.23 | Perf 10Y | -99.28% |
| Dividend Ex-Date | - | Quick Ratio | 5.69 | EPS Q/Q | 2.57% | Profit Margin | - | RSI (14) | 40.24 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.69 | Sales Q/Q | - | SMA20 | -14.25% ($2.47) | Beta | 1.36 | Target Price | $17 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/7 | SMA50 | -11.6% ($2.4) | Rel Volume | 0.99 | Prev Close | $2.33 |
| Employees | 14 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 7.32% - | SMA200 | -44.87% ($3.85) | Avg Volume(3M) | 0.07M | Price | $2.12 |
| IPO | 2012/11/8 | Option/Short | Yes/Yes | Trades | 364 | Volume | 70,263 | Change | -9.01% |
🎀 This is a clinical-stage biotech company developing breast cancer therapeutics. Its lead candidate, (Z)-endoxifen, is a selective estrogen receptor modulator that is 100 times more potent than existing drugs. The company targets the full spectrum of breast cancer, from metastatic disease to prevention, and is headquartered in Seattle.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded about as much as usual. That is 99% of its average volume.
ATOS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +7.3% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.0%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #464 of 597 in the industry
Based on market cap of $21M.
IGC#461 IGC Pharma Inc $23M PER - 
IMMP#462 Immutep Limited ADR $22M PER - 
BSEM#463 BioStem Technologies Inc $21M PER - ATOS#464 Atossa Therapeutics Inc $21M PER - 
MCRB#465 Seres Therapeutics Inc $21M PER - 
FAQ
What kind of company is ATOS?
ATOS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ATOS?
The market cap of ATOS is approximately $21M, ranking 5,187 within its sector.
What is the 52-week high and low for ATOS?
ATOS has recorded a 52-week high of $14.85 and a low of $1.70.
